L03 AB ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica3

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-001292-21-FR
(EUCTR)
27/07/201805/06/2018Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 yearsDisease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Secondary Progressive Multiple Sclerosis
MedDRA version: 20.0;Level: PT;Classification code 10063400;Term: Secondary progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AVONEX
Product Name: BETAFERON
Product Code: L03 AB 08
Product Name: EXTAVIA
Product Name: REBIF
Product Name: PLEDIGRY
Product Name: COPAXONE
Product Name: AUBAGIO
Product Name: TECFIDERA
Product Name: GILENYA
Product Name: TYSABRI
Product Name: IMUREL
Product Name: NOVATREX
Product Name: CELLCEPT
Product Name: ENDOXAN
CHU de RennesNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
250 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance
2EUCTR2009-015502-19-GB
(EUCTR)
08/02/201017/03/2010A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial - PRISMS-15A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial - PRISMS-15 Multiple Sclerosis
MedDRA version: 12.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis
Trade Name: Rebif
Product Name: Rebif
Product Code: L03 AB07
Other descriptive name: INTERFERON BETA-1A
Merck Serono SA – GenevaNULLNot RecruitingFemale: yes
Male: yes
300Finland;Germany;United Kingdom;Belgium;Sweden
3EUCTR2008-006226-34-BE
(EUCTR)
23/12/200929/09/2009A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis plus a long-term extension period. - TENEREA multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis plus a long-term extension period. - TENERE Multiple sclerosisProduct Name: Teriflunomide
Product Code: HMR1726
INN or Proposed INN: Teriflunomide
Product Name: Teriflunomide
Product Code: HMR1726
INN or Proposed INN: Teriflunomide
Trade Name: Rebif
INN or Proposed INN: INTERFERON BETA-1A
Trade Name: Rebif
Product Code: L03 AB
INN or Proposed INN: INTERFERON BETA-1A
Trade Name: Rebif
Product Name: L03 AB
INN or Proposed INN: INTERFERON BETA-1A
sanofi-aventis recherche et developmentNULLNot RecruitingFemale: yes
Male: yes
300France;Czech Republic;Hungary;Spain;Belgium;Germany;United Kingdom;Italy